Fast paced sales growth sets a new company record and underscores the continued worldwide acceleration in demand for SonaCare's unique HIFU platform technology

CHARLOTTE, NC -- SonaCare Medical, LLC, the global leader in high intensity focused ultrasound (HIFU), announced record-setting sales of 15 HIFU devices over the past twelve months pointing to a steady worldwide surge in demand for the company's ablation technology. 

SonaCare Medical, LLC, the global leader in urologic high intensity focused ultrasound (HIFU), is proud to provide platinum support for the upcoming 7th International Symposium on Focal Therapy and Imaging in Prostate & Kidney Cancer. This year's symposium takes place at the Langham Huntington Resort in Pasadena, CA from August 21st to 23rd and includes faculty members from seven countries who have put together a comprehensive scientific program including multiple HIFU sessions.

May 27, 2014 CHARLOTTE, NC -- Medical device manufacturer SonaCare Medical reports continuing strong European sales as well as a positive outlook in light of official guideline changes for prostate cancer therapy. The company has further invested in the European market by adding its newest generation high intensity focused ultrasound ("HIFU") equipment to the HIFU center of excellence at University College of London.

Director of Sales added. Commercialization personnel to be placed in targeted metropolitan areas, to bolster company's expanding US equipment sales.

TUESDAY, MAY 13, 2014 CHARLOTTE, NC -- SonaCare Medical, LLC is experiencing significant growth of its FDA cleared Sonatherm® offering with sales to both major academic and luminary sites. To support its accelerating growth, the company has hired Tres Glenn, an experienced urology sales executive, to the newly created position of Director of Sales for the U.S. The impetus for this hire is to further capitalize on the growing demand for the company's new 510K cleared Sonatherm® Laparoscopic Surgical Ablation System. Beginning this summer, the company also plans to add sales and clinical support personnel in several core metropolitan areas to address the increasing demand for its new focused ultrasound offering.

THURSDAY, MAY 8, 2014 CHARLOTTE, NC. - SonaCare Medical, LLC, a leader in minimally invasive high intensity focused ultrasound (HIFU) technology, today announced that the U.S. Food and Drug Administration (FDA) has tentatively scheduled a Gastroenterology and Urology Devices Advisory Committee Panel meeting on October 2, 2014 to review the Company's Premarket Approval (PMA) application for Sonablate® 450 for the treatment of recurrent prostate cancer following external beam radiation treatment (EBRT) in the U.S.

Strong demand for minimally invasive ablative therapies results in four HIFU device sales in first quarter of 2014 

Charlotte, N.C., April 2, 2014 -- SonaCare Medical, LLC, a leader in minimally invasive high intensity focused ultrasound (HIFU) technology, starts 2014 with strong first quarter device sales. SonaCare Medical sold two Sonablate® HIFU devices for the non-invasive treatment of prostate cancer in the international market and two Sonatherm® laparoscopic surgical soft tissue ablation systems in the United States during the quarter. 

Page 6 of 9

HIFU company

Contact

10130 Perimeter Pkwy, Suite 250
      Charlotte, NC 28216

(888) 874-4384

info@SonaCareMedical.com

Mon - Fri: 9:00 - 5:00

Latest News

23 May 2017

C-code goes into effect on July 1, 2017 affording greater opportunity to prostate patients in the United States Charlotte, NC, May 23, 2017 – SonaCare Medical, leading developer and manufacturer...

11 April 2017

Charlotte, NC (PR Newswire) April 11th, 2017 - SonaCare Medical, the leading developer and manufacturer of high intensity focused ultrasound (HIFU) technologies, announces the launch of an International Sonablate HIFU...